Scarica l'app Stockscreener
66.23
0.33%
0.22
Pre-mercato:
66.09
-0.14
-0.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$66.01
Aprire:
$66.08
Volume 24 ore:
1.46M
Relative Volume:
1.16
Capitalizzazione di mercato:
$5.26B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-11.15
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
+1.32%
1M Prestazione:
+13.54%
6M Prestazione:
+64.38%
1 anno Prestazione:
+72.07%
Intervallo 1D:
$65.36
$67.24
Intervallo di 1 settimana:
$62.32
$67.24
Portata 52W:
$35.51
$67.40
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
66.23 | 5.24B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
How PTC Therapeutics Inc. stock compares to growth peersWeekly Trend Summary & Free Technical Confirmation Trade Alerts - newser.com
Using RSI to spot recovery in PTC Therapeutics Inc.Analyst Upgrade & Low Drawdown Trading Strategies - newser.com
PTC Therapeutics, Inc. Hits New 52-Week High of $67.40 - Markets Mojo
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells 3,375 Shares of Stock - MarketBeat
PTC Therapeutics' (PTCT) Hold (C-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Using flow based indicators on PTC Therapeutics Inc.2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com
Chart based analysis of PTC Therapeutics Inc. trendsQuarterly Performance Summary & Fast Entry and Exit Trade Plans - newser.com
Ptc Therapeutics exec. VP Boulding sells $214k in shares By Investing.com - Investing.com Canada
Relative strength of PTC Therapeutics Inc. in sector analysisTrade Exit Summary & Free Safe Entry Trade Signal Reports - newser.com
What does recent volatility data suggest for PTC Therapeutics Inc.Weekly Stock Report & Short-Term High Return Ideas - newser.com
Robeco Institutional Asset Management B.V. Buys Shares of 5,733 PTC Therapeutics, Inc. $PTCT - MarketBeat
RBC Raises Price Target on PTC Therapeutics to $70 From $63, Keeps Outperform Rating - MarketScreener
Mark Elliott Boulding Sells 2,266 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
Allan Steven Jacobson Sells 12,000 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Insider Sells $3,632,750.00 in Stock - MarketBeat
Allan Jacobson sells PTC Therapeutics shares for $780,000 - Investing.com
Ptc therapeutics exec. VP Boulding sells $1.6m in stock - Investing.com
Emma Reeve, PTC Therapeutics director, sells $1.68m in shares - Investing.com
Duchenne Muscular Dystrophy Market Report 2034: Epidemiology, Pipeline Therapies, and Recent Regulatory Approvals by DelveInsight | Featuring Sarepta Therapeutics, PTC Therapeutics, Nippon Shinyaku, S - Barchart.com
Real time breakdown of PTC Therapeutics Inc. stock performance2025 Earnings Surprises & Low Drawdown Investment Strategies - newser.com
Evaluating PTC Therapeutics Inc. with trendline analysisJuly 2025 Setups & Verified Technical Signals - newser.com
PTC Therapeutics Stock Sees Momentum Amidst Corporate Developments - StocksToTrade
PTC Therapeutics Bolsters Workforce Amid Stock Option Grants - timothysykes.com
Analysts Shine Spotlight on PTCT in Friedreich’s Ataxia Talks - timothysykes.com
Why PTC Therapeutics Inc. (BH3) stock could outperform next yearDollar Strength & Reliable Intraday Trade Alerts - newser.com
Will PTC Therapeutics Inc. (BH3) stock outperform energy sector in 2025 - newser.com
How to build a custom watchlist for PTC Therapeutics Inc.Quarterly Portfolio Review & High Conviction Trade Alerts - newser.com
Will PTC Therapeutics Inc. rebound enough to break evenCEO Change & Weekly Momentum Picks - newser.com
Is PTC Therapeutics Inc. (BH3) stock among top earnings plays2025 Price Momentum & AI Enhanced Trading Signals - newser.com
PTC Therapeutics Announces New Employee Stock Grants Amid Strategic Developments - timothysykes.com
PTCT Sees Strategic Staff Expansion Amidst Recent Developments - timothysykes.com
Will uniQure’s Results Pressure PTC Therapeutics’ (PTCT) Rare Disease Leadership and Revenue Ambitions? - Sahm
Using AI based signals to follow PTC Therapeutics Inc.2025 Historical Comparison & Reliable Intraday Trade Plans - newser.com
Ptc Therapeutics stock hits 52-week high at 63.33 USD By Investing.com - Investing.com Nigeria
PTC Therapeutics (NASDAQ:PTCT) Hits New 1-Year HighWhat's Next? - MarketBeat
Ptc Therapeutics stock hits 52-week high at 63.33 USD - Investing.com India
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
19,475 Stock Options, 39,060 RSUs: PTC Therapeutics Awards Major Inducement Grants to New Employees - Stock Titan
PTC Therapeutics to Participate at Upcoming Investor Conferences - GuruFocus
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ptc Therapeutics Inc Azioni (PTCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 07 '25 |
Sale |
63.43 |
3,375 |
214,091 |
103,901 |
| Reeve Emma | Director |
Oct 03 '25 |
Option Exercise |
35.73 |
25,562 |
913,334 |
20,332 |
| Reeve Emma | Director |
Oct 03 '25 |
Sale |
65.96 |
25,562 |
1,686,024 |
10,332 |
| Jacobson Allan Steven | Director |
Oct 03 '25 |
Option Exercise |
30.86 |
12,000 |
370,320 |
29,451 |
| Jacobson Allan Steven | Director |
Oct 03 '25 |
Sale |
65.00 |
12,000 |
780,000 |
17,451 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 03 '25 |
Option Exercise |
39.42 |
22,655 |
893,060 |
122,025 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 06 '25 |
Option Exercise |
39.42 |
2,266 |
89,326 |
106,167 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 03 '25 |
Sale |
65.82 |
22,655 |
1,491,100 |
103,901 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 06 '25 |
Sale |
65.07 |
2,266 |
147,449 |
103,901 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Oct 03 '25 |
Option Exercise |
30.86 |
55,000 |
1,697,300 |
152,183 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):